Atossa Therapeutics, Inc. (ATOS) News
Track canonical SquawkNews coverage tagged to ATOS, Atossa Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Atossa to Issue CVRs Giving Shareholders Claim on 25% of First Voucher Proceeds, Capped at $50M
Atossa will issue one contingent value right per share giving holders a contractual claim to 25% of net proceeds from the company's first qualifying rare pediatric disease priority review voucher, capped at $50 million.K
REGULATION | Sep 29, 2026, 12:03 PM UTC
L
Atossa Therapeutics, Inc. (ATOS) Plans CVR Paying Up To $50M From Potential PRV
Atossa approved issuing one CVR per share, entitling holders to 25% of net proceeds from monetizing its first qualifying FDA priority review voucher, capped at $50M. No product is approved and no voucher has been awarded
REGULATION | Sep 29, 2026, 12:01 PM UTC
L
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafterCVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review vouch
NEWS | Sep 29, 2026, 12:00 PM UTC
L
ATOS - Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
ATOS - Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
NEWS | Sep 24, 2026, 12:01 PM UTC
L
ATOS ATOS - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti- Cancer Activity in
ATOS ATOS - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti- Cancer Activity in ER- Positive Breast Cancer
EQUITY | Jul 28, 2026, 12:31 PM UTC